Social Media in the Pharmaceutical Industry

SMi Group22 - 23 January 2018, London, UK.
Social media is the perfect channel for pharmaceutical companies to educate, market, listen and connect with customers, patients and physicians. How the pharmaceutical industry utilize social media is particularly complex as regulators such as the FDA have not yet written the rules about how pharmaceuticals can engage with potential customers and patients.

Join SMi's 10th Annual Social Media in the Pharmaceutical Industry Conference to learn the best way your company can benefit from social media. Hear from industry experts on how to leverage social media platforms to develop a robust digital strategy and discuss the latest challenges and techniques in the field of 'social pharma'.

How Will You Benefit?

Network and learn from leading professionals such as:
  • Emma Sutcliffe, Director, Patient Engagement & Innovation, NexGen Healthcare
  • Tughan Demirbilek, Strategy & Operations Director, Bristol-Myers Squibb
  • Marcel Gmünder, Global Head, Digital Health Group, Roche Diabetes Care
  • Elodie Douangmanivanh, Head of Digital Services, MSD
  • Sebastian Soithongsuk, Global Content Manager Digital Comms, GSK
  • Aslihan Unal, Digital Strategy Group Manager, Janssen
  • Hervé Dumas, Patients’ Technology Solutions Lead, UCB
  • Sarah Holiday, Social Media Strategy Lead, Pfizer

Some Featured Highlights will include:

  • Hear how Janssen create powerful pharmaceutical social media strategies enabling patient engagement.
  • Learn how to build integrated, impactful social media strategies with Pfizer.
  • Discuss the potential of wearable technologies creating behavioural changes for patients with UCB.
  • Discover with GSK how to make your social media content less "promotional" and more about storytelling.
  • Examine how Bristol Myers-Squibb create an excellent digital strategy whilst engaging patients.

For further information and to register, please visit:
http://www.social-media-pharma.com/wpn

Early-Bird Rates

  • Book by 31st October and save £200
  • Book by 30th November and save £100

About SMi Group
The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

FDA approves expanded use of Gardasil 9 to include…

The U.S. Food and Drug Administration approved a supplemental application for Gardasil 9 (Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant) expanding the approved...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...

Pfizer announces Executive Leadership Team

Pfizer Inc. (NYSE:PFE) today announced its executive team that will report to Albert Bourla, incoming Chief Executive Officer, coincident with the commencement of his new...